Patent ID: 11865175
Assignee: CEDARS-SINAI MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 18:
19. A method for reducing and/or eliminating donor specific anti-human leukocyte antigen (HLA) antibodies in a subject that has undergone organ transplantation, the method consisting of administering to the subject a therapeutically effective amount of intravenous immunoglobulin (IVIG) and an anti-CD20 agent in one or more pharmaceutical compositions to the subject after the organ transplantation, or
administering a therapeutically effective amount of the IVIG, the anti-CD20 agent, and one or more of antithymocyte globulin, alemtuzumab, a glucocorticoid, mycophenolate mofetil, tacrolimus, and antibiotics, in one or more pharmaceutical compositions to the subject after the organ transplantation,
wherein the anti-CD20 agent comprises rituximab, ofatumumab, obinutuzumab, tositumomab, ocaratuzumab, ocrelizumab, TRU-015, IMMU-106, or a combination thereof; and
wherein, if the subject did not receive rituximab before the transplantation, the IVIG and the anti-CD20 agent are administered only between 3 days and 10 days after the transplantation, or the IVIG is administered only between 7 days and 14 days after the transplantation and the anti-CD20 agent is administered only between 14 days and 21 days after the transplantation, or
wherein, if the subject received the rituximab before the transplantation, the IVIG and the anti-CD20 agent are administered only between 3 days and 10 days after the transplantation.